Gag P2/NC and pol genetic diversity, polymorphism, and drug resistance mutations in HIV-1 CRF02_AG- and non-CRF02_AG-infected patients in Yaounde, Cameroon.
Method: These transmitted DRMs included major resistance mutations to NRTIs such as M184V, T69D, T215F, K65R, and Y115F; and major resistance mutations to non-Nucleoside/Nucleotide Reverse Transcriptase Inhibitors (NNRTIs) such as Y181C, K103N, P225H, V108I, K101E, Y188L, E138Q, and L100I (Table 2).
Table: E138Q
Week 48 resistance analysis of Elvitegravir/Cobicistat/Emtricitabine/Tenofovir DF versus Atazanavir + Ritonavir + Emtricitabine/Tenofovir DF in HIV-1 infected women (WAVES study GS-US-236-0128).
Abstract: A62V, V90I, K103N, or E138A/G/K/Q; 68-82%) demonstrated virologic suppression at week 48, with no resistance development except for one patient with M184V and pre-existing K103N in the ATV + RTV + FTC/TDF group.
Result: E138A/K/Q, a mutation related to the NNRTIs etravirine (ETR) and rilpivirine (RPV) was found in 8.6% of subjects, although these drugs are not currently available and not part of the standard treatment regimen in South Africa.
Result: Excluding E138A/K/Q among NNRTI mutations reduced the NNRTI resistance prevalence from 65.2 to 62.5%.
Discussion: In fact, in the Stanford Drug Resistance database, subtype C strains from drug exposed patients have a higher prevalence of the E138A/K/Q mutation compared to other group M strains (8-9.5% vs.
Discussion: Similarly, we speculate that the occurrence of the E138A/K/Q mutation could be due to the codon usage of subtype C
Etravirine combined with antiretrovirals other than darunavir/ritonavir for HIV-1-infected, treatment-experienced adults: Week 48 results of a phase IV trial.
Usefulness of an HIV DNA resistance genotypic test in patients who are candidates for a switch to the rilpivirine/emtricitabine/tenofovir disoproxil fumarate combination.
PMID: 27231280
2016
The Journal of antimicrobial chemotherapy
Abstract: Rilpivirine/emtricitabine/tenofovir disoproxil fumarate RAMs studied were K65R, L100I, K101E/P, E138A/G/K/R/Q, V179L, Y181C/I/V, M184V/I, Y188L, H221Y, F227C and M230I/L in the RT.
Treatment failure and drug resistance in HIV-positive patients on tenofovir-based first-line antiretroviral therapy in western Kenya.
PMID: 27231099
2016
Journal of the International AIDS Society
Table: E138Q
Role of Rilpivirine and Etravirine in Efavirenz and Nevirapine-Based Regimens Failure in a Resource-Limited Country: A Cross- Sectional Study.
Method: RT-RAMs were identified and analyzed by using the Stanford Drug Resistance Database for V90I, A98G, L100I/V, K101E/P/Q/H/N, K103N/S/T/Q/E/H/R, V106A/M/I, V108I, E138A/K/Q/G/R, V179D/E/T/F/L, Y181C/I/V/S/F/G, M184I, Y188C/H/L/F, G190A/S/E/Q/C/V/T, H221Y,
Clinical Outcomes of Virologically-Suppressed Patients with Pre-existing HIV-1 Drug Resistance Mutations Switching to Rilpivirine/Emtricitabine/Tenofovir Disoproxil Fumarate in the SPIRIT Study.
Abstract: Mutations potentially affecting RPV activity, including E138A/G/K/Q, Y181C, and H221Y, were detected in isolates from 11 patients by one or both assays.
Biochemical characterization of a multi-drug resistant HIV-1 subtype AG reverse transcriptase: antagonism of AZT discrimination and excision pathways and sensitivity to RNase H inhibitors.
Result: According to the HIV Drug Resistance Database (http://hivdb.stanford.edu/), K101Q, E138Q and exchanges at position V179 are also detected in patients treated with EFV.
HIV mutation literature information.
PMID: 
2017
Scientific reports
Browser Board
Co-occurred Entities
Filtrator
ViMRT